CREON Clinical Efficacy
Trapnell Study:
Children and adults with EPI due to CF1,8
TREATMENT PERIOD OF 5 DAYS
Treatment-Related Improvement in Fat Absorption
Mean CFA (%)
100
80
60
40
20
0
n=29
Mean difference in CFA was 41% (P<0.001)
- Significant improvement in CFA in patients with EPI due to cystic fibrosis aged 12 to 43 years
- Patients received CREON at a dose of 4,000 lipase units per gram of fat per day or placebo and had a dietary fat intake ≥90 g per day
- The most common adverse reactions reported in this study were gastrointestinal-related, dizziness, and cough
Graff Study:
Children with EPI due to CF1,7
TREATMENT PERIOD OF 5 DAYS
Treatment-Related Improvement in Fat Absorption
Mean CFA (%)
100
80
60
40
20
0
n=16
Mean difference in CFA was 35% (P<0.001)
- Significant improvement in CFA in pediatric patients aged 7 to 11 with EPI due to cystic fibrosis (CF)
- Patients received CREON at a dose of 4,000 lipase units per gram of fat per day or placebo and had a dietary fat intake ≥90 g per day
- The most common adverse reactions reported in this study were vomiting and headache
Whitcomb Study: Adults with EPI due
to CP or pancreatectomy1,9
TREATMENT PERIOD OF 7 DAYS
Treatment-Related Improvement in Fat Absorption
Mean CFA (%)
100
80
60
40
20
0
n=16
Mean difference in CFA was 35% (P<0.001)
n=28
n=24
Mean difference in CFA was 21% (P<0.0001)
- Significant improvement in CFA in adult patients aged 32 to 75 with EPI due to chronic pancreatitis (CP) and pancreatectomy
- Patients received CREON at a dose of 72,000 lipase units per meal (3 meals) and 36,000 lipase units per snack (2 snacks) or placebo and had a dietary fat intake ≥100 g per day
- The most common adverse reactions reported in this study were related to glycemic control and were reported more commonly during CREON treatment than during placebo treatment
normal CNA1,7,8
Trapnell Study:
Children and adults with EPI due to CF1,8
TREATMENT PERIOD OF 5 DAYS
Treatment-Related Improvement in Protein Absorption
Mean CNA (%)
100
80
60
40
20
0
n=29
Mean difference in CNA was 37% (P<0.001)
- Significant improvement in CNA in patients with EPI due to cystic fibrosis aged 12 to 43 years
- The primary efficacy measurement was CFA. The secondary efficacy measurement was CNA
- Patients received CREON at a dose of 4,000 lipase units per gram of fat per day or placebo and had a dietary fat intake ≥90 g per day
- The most common adverse reactions reported in this study were gastrointestinal-related, dizziness, and cough
Graff Study:
Children with EPI due to CF1,7
TREATMENT PERIOD OF 5 DAYS
Treatment-Related Improvement in Protein Absorption
Mean CNA (%)
100
80
60
40
20
0
n=16
Mean difference in CNA was 35% (P<0.001)
- Significant improvement in CNA in pediatric patients aged 7 to 11 with EPI due to cystic fibrosis (CF)
- The primary efficacy measurement was CFA. The secondary efficacy measurement was CNA
- Patients received CREON at a dose of 4,000 lipase units per gram of fat per day or placebo and had a dietary fat intake ≥90 g per day
- The most common adverse reactions reported in this study were vomiting and headache

CREON patient support programs
offer financial, multivitamin, and
educational support
Programs